IMPACT PH Logo

IMPACT: IMProving Approaches to Care and Treatment

IMPACT LIVE, a free certified on-demand series of dinner, grand rounds, breakfast and virtual lectures led by renowned faculty. In various locations throughout the country, these programs focus on the latest medical advances and provide novel approaches to achieving better patient outcomes. 

To request or register for an IMPACT LIVE program, simply click on the topic below, choose a speaker and select a date. 

Good food, peer to peer interaction and quality certified medical education in one free event!

Select one of our cutting-edge, disease specific topics

Choose a speaker from our renowned faculty

Select the date, venue, and request a program!



Program Overview

Pulmonary arterial hypertension (PAH) is a complex disease with multiple etiologies. The IMPACT PH program was established to afford physicians and allied health professionals up-to-date information on this disease in order to facilitate patient identification, establish an effective diagnosis and to understand the risks and benefits of the various treatments now available.

The learning modules in this program cover a range of topics, from the more general aspects of PAH to specific situations, such as pulmonary hypertension associated with connective tissue diseases, like scleroderma. Whenever practical, a case-based approach is used so that health professionals can follow the diagnostic pathway, using the appropriate tools, to finally arrive at the PAH diagnosis.

While each module addresses a set of core learning objectives, the content is scalable to meet the needs of each individual audience.

Target Audience

This activity has been designed to meet the educational needs of physicians, registered nurses, and other healthcare professionals involved in the care of patients with pulmonary hypertension. 

Educational Objectives

After completing this activity, the participant should be better able to:
  • Describe the latest data supporting the new and emerging PAH medications and delivery systems
  • Discuss the use of aggressive combination therapy approaches to PAH
  • Distinguish the current and emerging practice guidelines for Group 1 PAH and non-Group 1 PH
  • Restate up-to-date clinical evidence regarding new treatment modalities and development programs
  • Differentiate the timing of various therapy in the course of the patient's disease and whether earlier action on the prostacyclin pathway alone or in combination therapy benefits patients clinically
  • Describe the rationale for switching therapies to take advantage of alternative attack points in PAH pathophysiology

 

CME/CNE Certified On-Demand
Lecture Series

Upcoming Lectures

|
Speaker:
Topic:
Format:
Date:
Time:
Location:
Accreditation:



Available Topics


Managing Connective Tissue Disease (CTD)-Associated Pulmonary Arterial Hypertension (PAH): Advanced Screening and New Treatment Strategies

Program Summary

This program is intended for physicians and nurses dealing with the diagnosis and treatment of patients with pulmonary hypertension resulting from connective tissue disease (CTD). Specific attention is paid to the prevalence, morbidity and predictors of mortality associated with CTD-PH. The signs and symptoms of CTD-PH are reviewed as is the importance of screening for PH in the CTD patient. Treatment approaches for CTD-PH are reviewed with emphasis on combination strategies. Finally, the role of lung transplantation in the treatment algorithm is considered along with transplantation associated survival.

Learning Objectives
  • Identify the incidence, morbidity, and predictors of mortality of pulmonary arterial hypertension (PAH) in persons with connective tissue disease (CTD)
  • Recognize the signs and symptoms of PAH in patients with CTD
  • Discuss the importance of screening for pulmonary hypertension (PH) in CTD and its impact on mortality
  • Explain the need for early diagnosis and treatment of CTD-associated PAH
  • Employ current treatment strategies for CTD-associated PAH including combination therapies
  • Describe the role of lung transplantation in the therapeutic algorithm and its effect on survival

Case Studies in Pulmonary Hypertension: Not all PH is PAH!


Program Summary

This program is intended for all healthcare practitioners involved in the identification, diagnosis and treatment of patients with PAH. The case-based program begins with a consideration of the diagnosis of a patient with PAH and the specific, and definitive tests required to secure the diagnosis. Emphasis is placed on the necessity of the right heart catheterization as the defining diagnostic test. Additional cases are available for presentation, based on the audience make-up, and include patients with CTEPH, scleroderma and PH due to left heart disease. In each case presentation, treatment options are considered.

Learning Objectives
  • Describe the signs and symptoms of pulmonary hypertension
  • Discuss the most current diagnostic algorithm for pulmonary hypertension
  • Compare the key diagnostic tests for pulmonary hypertension and the role of right heart catheterization in confirming PH diagnosis
  • Discuss the characteristics, diagnosis and treatment of CTEPH
  • Differentiate between left heart disease, PH due to left heart disease, and pulmonary arterial hypertension
  • Discuss the current treatment algorithm for pulmonary hypertension and the available treatments

Current Concepts in The Diagnosis and Treatment of Pulmonary Hypertension


Program Summary

Detection, diagnosis and treatment of pulmonary hypertension, in any of its forms, presents challenges to the health care practitioner. This program examines the presentation of pulmonary hypertension, the pathways to correct diagnosis and options for treatment. The program uses a case-based approach to lead the viewer through the steps involved in creating a treatment strategy. In addition, some of the clinical evidence supporting recent additions to the medical treatment options for pulmonary hypertension are considered.

Learning Objectives
  • Describe the process for the differential diagnoses of pulmonary hypertension (PH) & pulmonary arterial hypertension (PAH)
  • List key echocardiographic features that may indicate PAH
  • Explain the role for right heart catheterization in the diagnosis of PAH
  • Discuss the current definition of PAH
  • Review the classification of pulmonary hypertension according to the 2013 WSPH Nice Guidelines
  • Utilize currently available medical treatments, strategies, and goals for PAH treatment

Managing Pulmonary Hypertension Medication: Side Effects and Titrations


Program Summary

Management of the patient with pulmonary hypertension can often be complex. In part, some of the major issues encountered in treating this spectrum of disease revolve around medication side effects and the time and effort needed to establish correct dosing of drugs. This program reviews the titration of pulmonary hypertension medications to achieve optimal efficacy balanced against side effects. As medication doses increase so do side effects. The presentation also explores how side effects can be managed to bring optimal benefit to the patient.

Learning Objectives
  • Review the therapeutic pathways targeted to treat PAH
  • Discuss common adverse events from current approved PH medications
  • Describe means to manage side effects of PH medications in order to keep patients on therapy
  • Review common practices for titration of PH medications

Confronting CTEPH IN 2018: Surgical and Medical Options for Treatment


Program Summary

Chronic thromboembolic pulmonary hypertension (CTEPH) remains a constant presence in the spectrum of pulmonary hypertension diseases. Yet despite its constant presence the annual incidence has been variable. Fortunately, new evidence regarding treatment has become available. In this module, the incidence of CTEPH is reviewed along with emerging surgical options for treatment. In addition, the impact of medical treatment options on morbidity and mortality is considered as part of an overall update on this disease.

Learning Objectives
  • Review the proposed pathophysiological mechanisms of CTEPH
  • Examine the incidence, prevalence risk factors and clinical presentation of CTEPH
  • Utilize the current recommended diagnostic approach to patients with suspected CTEPH
  • Employ current recommended surgical approaches to CTEPH and recent developments in surgical strategies for dealing with pulmonary emboli
  • Review medical therapies for CTEPH with emphasis on efficacy, safety and impact on quality of life
  • Debate medical treatment in post-PEA or BPA patients with residual PH

Diagnostic Techniques for the Determination of PH: Physical and Imaging Processes


Program Summary

Pulmonary hypertension has multiple etiologies and can easily be confused with other pulmonary and vascular disorders. The diagnostic process for pulmonary hypertension is well outlined but those health care providers less familiar with the disease can benefit from an understanding of the essential components of the diagnostic process. This program examines the current international guidelines for pulmonary hypertension diagnosis with a focus on the specific techniques used to insure correct determination of the presence and severity of pulmonary hypertension. Most importantly, strategies to differentiate WHO Group 1 PH from other forms is considered.

Learning Objectives
  • Review the different forms of pulmonary hypertension (PH)
  • Describe different techniques, including physical exam and imaging modalities, for the diagnosis of pulmonary hypertension
  • List key elements on each modality that can help diagnose PH
  • Find important elements to distinguish between the different forms of PH
  • Emphasize on the importance of a complete and methodical algorithm in the diagnosis of PH

PAH Therapy: Scaling Treatment to The Level of Risk


Program Summary

Modern management of PAH patients has expanded significantly in recent years with addition of novel therapies whose approval has been based on morbidity and mortality endpoints. Current international consensus guidelines for treatment have also been updated to reflect a more aggressive, combination therapy approach based on treatment decisions guided by each patient’s risk status. This program examines the necessities of creating treatment strategies based on each patient’s risk for morbidity and mortality. More importantly, the need for regular risk assessment is discussed with an eye towards ensuring that any change in risk is detected in a timely manner and treatment is adjusted accordingly.

Learning Objectives
  • Review current international guidelines treating risk associated morbidity and mortality in PH patients
  • Discuss the necessity for recurring risk assessment in PH
  • Examine essential available clinical data supporting aggressive combination therapy of PH to reduce risk of morbidity and mortality
  • Learn the current concepts of risk-based treatment of PH and the goals of treatment based on current guidelines

Pictures Tell a Thousand Words: Imaging to Diagnose Chronic Thromboembolic Pulmonary Hypertension


Program Summary

Chronic thromboembolic pulmonary hypertension (CTEPH) is a special class (WHO Group 4) of pulmonary hypertension with a 2-3 year mortality of 10-20% at 3 years and one for which correct diagnosis relies on modern medical imaging techniques. This program reviews some of the essential imaging techniques used to determine the presence or absence of CTEPH in patients presenting with symptoms. The session reviews the etiology of CTEPH and the current international consensus algorithm for diagnosis before examining specifics of the various imaging techniques used to elucidate chronic pulmonary emboli. These diagnostic tests are essential for precise, early diagnosis of this disease as a prelude to development of surgical or medical treatment strategies.

Learning Objectives
  • Review the risk factors and etiology of CTEPH
  • Discuss the current international consensus recommendations for the diagnosis of CTEPH
  • Describe the imaging technologies used in the current diagnostic detection of CTEPH
  • Debate the use of exercise testing to uncover otherwise hidden CTEPH


Accreditation Information

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Total CME.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates each live activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Confronting CTEPH IN 2018: Surgical and Medical Options for Treatment
  • Diagnostic Techniques for The Determination of Pulmonary Hypertension: Physical and Imaging Processes
  • Pictures Tell a Thousand Words: Imaging to Diagnose Chronic Thromboembolic Pulmonary Hypertension
  • PAH Therapy: Scaling Treatment to the Level of Risk

The Postgraduate Institute for Medicine designates each live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Case Studies in Pulmonary Hypertension: Not All PH is PAH!
  • Managing Pulmonary Hypertension Medication: Side Effects and Titrations
  • Managing Connective Tissue Disease (CTD)-Associated Pulmonary Arterial Hypertension (PAH): Advanced Screening and New Treatment Strategies
  • Current Concepts in The Diagnosis and Treatment of Pulmonary Hypertension

Continuing Nursing Education
The maximum number of hours awarded for each Continuing Nursing Education activity is 0.5 contact hour.

  • Confronting CTEPH IN 2018: Surgical and Medical Options for Treatment
  • Diagnostic Techniques for The Determination of Pulmonary Hypertension: Physical and Imaging Processes
  • Pictures Tell a Thousand Words: Imaging to Diagnose Chronic Thromboembolic Pulmonary Hypertension
  • PAH Therapy: Scaling Treatment to the Level of Risk

The maximum number of hours awarded for each Continuing Nursing Education activity is 1.0 contact hour.

California Board of Registered Nursing
Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.0 contact hour.

  • Case Studies in Pulmonary Hypertension: Not All PH is PAH!
  • Managing Pulmonary Hypertension Medication: Side Effects and Titrations
  • Managing Connective Tissue Disease (CTD)-Associated Pulmonary Arterial Hypertension (PAH): Advanced Screening and New Treatment Strategies
  • Current Concepts in The Diagnosis and Treatment of Pulmonary Hypertension

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Fee Information
There is no fee for these educational activities.

Jointly provided by Postgraduate Institute for Medicine and Total CME

These activities are supported by independent educational grants from Actelion Pharmaceuticals US, Inc., Arena Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Inc., and United Therapeutics Corporation.



Available Formats

Grand Rounds
Your institution will select a faculty presenter and topic, and provide the in-hospital venue. Mentor Meetings and Events will work with an on-site representative to assist with logistical planning as needed.

Dinner Meeting
Held at a restaurant, this program will include the selection of a speaker and topic(s) for a one-hour program with question-and- answer session (select one 1.0 CME/CE topic, or two 0.5 CME/CE topics). Site selection will comply with ACCME and PhRMA guidelines, and will include a modest meal selection. These are generally private programs for an individual practice group.

Lunch (or breakfast) Meeting
Held at your practice, this program includes a one-hour program with question-and-answer session (select one 1.0 CME/CE topic, or two 0.5 CME/CE topics) . This format will include a modest meal selection, compliant with ACCME and PhRMA guidelines. This program may be for a single practice, or multiple practice groups.

Symposium
This format may include multiple speakers and lecture topics. Please speak to a representative at Mentor Meetings and Events to plan this event.

Compliance with Sunshine Act

The National Physician Payment Transparency Program (Sunshine Act) is a section of the Patient Protection and Affordable Care Act of 2010 that requires pharmaceutical and medical device companies to report to the Federal government certain payments (e.g. meals and other meeting expenses) they make to physicians and teaching hospitals. IMPACT PH programs fully comply with the Sunshine Act and, as a result, payments may be reportable based upon these requirements. For detailed information, please visit www.cms.gov.



IMPACT PH Steering Committee


Program Chair:

Vallerie McLaughlin, MD
Kim A. Eagle, MD, Endowed Professor of Cardiovascular Medicine
Associate Chief of Cardiovascular Medicine
Dept. of Internal Medicine/ Cardiovascular Medicine
University of Michigan
Ann Arbor, MI

Richard Channick, MD
Director, Pulmonary Hypertension and
Thromboendarterectomy Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Paul Forfia, MD, MS
Professor of Medicine
Director, Pulmonary Hypertension/Right Heart Failure and Pulmonary Thromboendarterectomy Program
Temple University
Philadelphia, PA

Dinesh Khanna, MD
Professor of Medicine,
Division of Rheumatology,
Department of Medicine
Director, Scleroderma Program
University of Michigan Medical Center
Ann Arbor, MI

Nick H. Kim, MD
Clinical Professor of Medicine
Pulmonary, Critical Care
and Sleep Medicine
Director, Pulmonary Vascular Medicine
University of California, San Diego
San Diego, California

Martha Kingman Liberty, FNP-C, DNP
Nurse Practitioner, Pulmonary Services
Heart and Lung Center
UT Southwestern Medical Center
Dallas, TX

Richard Krasuski, MD, FACC, FAHA, FESC 
Professor of Medicine and Pediatrics
Director, Adult Congenital Heart Disease Center
Director of Hemodynamic Research
Duke University Medical Center
Durham, NC

Ioana Preston, MD
Associate Professor of Medicine
Director, Pulmonary Hypertension Center
Director, Pulmonary Function Test Lab
Tufts Medical Center
Boston, Massachusetts

Rajan Saggar, MD
Associate Professor of Medicine
Director, Medical Intensive Care Unit
Lung & Heart-Lung Transplant
and PH Program
David Geffen School of Medicine
UCLA Medical Center
Los Angeles, California

Sean Studer, MD, MSc, FCCP
Clinical Associate Professor
New York University and
System Deputy Chief Medical Officer
NYC Health + Hospitals
New York City, New York

Victor Tapson, MD
Professor of Medicine
Division of Pulmonary and Critical Care
Cedars-Sinai Medical Center
Los Angeles, California

 

 



IMPACT PH Faculty

Raymond L. Benza, MD
Allegheny General Hospital
Pittsburgh, PA

 

Lynette Brown, MD, PhD
University of Utah
Salt Lake City, UT

 

Charles Burger, MD
Mayo Clinic 
Jacksonville, FL


Murali Chakinala, MD
Washington University School of Medicine
St. Louis, MO

 

Curt Daniels, MD
The Ohio State University
Werner Medical Center
Columbus, OH

 

Teresa De Marco, MD
University of California, San Francisco
San Francisco, CA


Jean Elwing, MD
University of Cincinnati
Cincinnati, OH

 

Peter Engel, MD
The Christ Hospital
Cincinnati, OH

 

Harrison Farber, MD
Boston University
Boston, MA


Aryeh Fischer, MD
University of Colorado School of Medicine
Denver, CO

 

Wayne Franklin, MD
Baylor College of Medicine
Houston, TX

 

Patricia George, MD
National Jewish Health
Denver, CO


Nicholas Hill, MD
Tufts University School of Medicine
Boston, MA

 

Wendy Hill, MSN, NP-C
Cedar-Sinai Medical Center
Los Angeles, California

 

Deborah Jo Levine, MD
UT Health Science Center
San Antonio, TX


Sandra Lombardi, RN
University of California, San Diego School of Medicine
La Jolla, CA

 

Roberto Machado, MD
Indiana University
Indianapolis, IN

 

Stephen Carl Mathai, MD, MHS, FCCP
Johns Hopkins University School of Medicine
Baltimore, MD


John McConnell, MD
Kentuckiana Pulmonary Associates
Louisville, KY

 

Susanne McDevitt, NP
University of Michigan Health System
Ann Arbor, MI

 

Omar A. Minai, MD, FCCP
Southside Regional Medical Center
Petersburg, VA


Ronald Oudiz, MD, FACP, FACC, FCCP
Harbor-UCLA Medical Center
Torrance, CA

 

Harold Palevsky, MD
Perelman School of Medicine of the University of Pennsylvania
Philadelphia, PA

 

Myung Park, MD
Houston Methodist Hospital
Houston, TX


Franck Rahaghi, MD, MHS, FCCP
Cleveland Clinic
Weston, FL

 

Amresh Raina, MD
Allegheny General Hospital
Temple University School of Medicine
Pittsburgh, PA

 

Ivan Robbins, MD
Vanderbilt University Medical Center
Nashville, TN


Zeenat Safdar, MD
Houston Methodist Hospital, Weill Cornell College of Medicine
Houston, TX

 

Jeffrey Sager, MD, MS
Santa Barbara Pulmonary Consultants
Santa Barbara, CA

 

Rajeev Saggar, MD
Banner University Medical Center
Phoenix, AZ


Robert Schilz, DO, PhD
Case Western Reserve University School of Medicine
Cleveland, OH

 

George Sokos, DO
West Virginia University/ Ruby Memorial Hospital
Morgantown, WV

 

Namita Sood, MD
The University of Texas Health Science Center at Houston
Houston, TX


Traci Stewart, RN, MSN, CHFN
University of Iowa
Iowa City, Iowa

 

Roxana Sulica, MD
NYU Langone Pulmonary Hypertension Program
New York, NY

 

Victor Test, MD
Texas Tech University Medical School
Lubbock, TX


Fernando Torres, MD
University of Texas Southwestern Medical Center
Dallas, TX

 

Anjali Vaidya, MD
Temple University Lewis Katz School of Medicine
Philadelphia, PA

 

Melisa Wilson, ARNP
Center for Pulmonary Hypertension and Cardiovascular Disease
Florida Hospital
Orlando, FL